Regencell Bioscience Holdings (RGC) Faces DOJ Scrutiny, Is The Stock Too Expensive?

Simply Wall St.07-06

Regencell Bioscience Holdings (RGC) is back in focus after disclosing cooperation with a U.S. Department of Justice investigation into trading in its shares, alongside mounting legal costs and going ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649619222?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-07-06 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649619222","market":"us","top_or_hot":-1,"title":"Regencell Bioscience Holdings (RGC) Faces DOJ Scrutiny, Is The Stock Too Expensive?","media":"Simply Wall St.","content":"<div>\n<p>Regencell Bioscience Holdings (RGC) is back in focus after disclosing cooperation with a U.S. Department of Justice investigation into trading in its shares, alongside mounting legal costs and going ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-rgc-faces-doj-scrutiny-is-the\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regencell Bioscience Holdings (RGC) Faces DOJ Scrutiny, Is The Stock Too Expensive?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegencell Bioscience Holdings (RGC) Faces DOJ Scrutiny, Is The Stock Too Expensive?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 04:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-rgc-faces-doj-scrutiny-is-the><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regencell Bioscience Holdings (RGC) is back in focus after disclosing cooperation with a U.S. Department of Justice investigation into trading in its shares, alongside mounting legal costs and going ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-rgc-faces-doj-scrutiny-is-the\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-rgc-faces-doj-scrutiny-is-the","article_id":"2649619222","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-rgc-faces-doj-scrutiny-is-the","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649619222","pubTimestamp":1783282746,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regencell Bioscience Holdings (RGC) is back in focus after disclosing cooperation with a U.S. Department of Justice investigation into trading in its shares, alongside mounting legal costs and going concern warnings.\nSee our latest analysis for Regencell Bioscience Holdings.\nAt a share price of $6.37, Regencell Bioscience Holdings has seen sharp selling pressure recently, with the 30 day share price return down 68.13% and the year to date share price return down 68.99%. The three year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RGC":"脑再生科技","BK4539":"次新股"},"translate_title":"Regencell Bioscience Holdings(RGC)面临司法部审查，该股是否太贵？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGC":1.5},"content_text":"Regencell Bioscience Holdings (RGC) is back in focus after disclosing cooperation with a U.S. Department of Justice investigation into trading in its shares, alongside mounting legal costs and going concern warnings. See our latest analysis for Regencell Bioscience Holdings. At a share price of $6.37, Regencell Bioscience Holdings has seen sharp selling pressure recently, with the 30 day share price return down 68.13% and the year to date share price return down 68.99%. The three year total shareholder return remains very large, hinting at how sentiment has swung as the Department of Justice investigation, going concern warnings, and lack of revenue have refocused attention on risk rather than past gains. If you want to see what else is moving as investors reassess higher risk stories, it could be worth scanning for 20 top founder-led companies With Regencell Bioscience Holdings now trading well below its recent offering price, yet still showing a very large three year total shareholder return, the key question is whether current risks are overdiscounted or if the market is already assuming future success. AdvertisementPreferred Price-to-Book Multiple of 2,588x: Is It Justified? Regencell Bioscience Holdings currently looks expensive on a simple yardstick, with its price implying a very high valuation compared to the book value of its equity. The price to book ratio compares the market value of the company to the accounting value of its net assets, so it is often used where earnings are not yet positive. For RGC, this multiple is 2,588.3x, while the company reports no revenue and a net loss of $7.05m. This means investors are effectively paying a very large premium over the balance sheet value for a business still in the development stage. Against peers, that premium stands out sharply. The US pharmaceuticals industry averages a P/B of 2.4x, and RGC also screens as expensive relative to its direct peer group average of 6.4x. Both comparisons underline how far current pricing sits above sector norms, even before considering that RGC remains unprofitable and has a negative return on equity. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 2,588.3x (OVERVALUED) However, the Department of Justice investigation and the company’s ongoing losses with no revenue mean that Regencell Bioscience Holdings could still face sharp swings in sentiment. Find out about the key risks to this Regencell Bioscience Holdings narrative. Next Steps Given how cautious this Regencell Bioscience Holdings story sounds, it makes sense to check the underlying data yourself and decide quickly where you stand. Start by weighing the 3 important warning signs. Looking for more investment ideas beyond Regencell Bioscience Holdings? If Regencell Bioscience Holdings has highlighted how concentrated single stock risk can feel, you can use that insight to broaden your opportunity set with a few focused stock lists.  Spot potential turnaround stories by checking out 20 elite penny stocks with strong financials that combine smaller market sizes with stronger balance sheets and business fundamentals than many expect. Target quality at a more grounded price by reviewing the 44 high quality undervalued stocks that pair solid cash flows with healthier financial positions. Reduce portfolio stress by focusing on 74 resilient stocks with low risk scores that score better on balance sheet strength, earnings consistency, and overall risk metrics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649619222","isCrawlerRequest":true}